60 Degrees Pharmaceuticals Inc. (SXTP)
SXTP trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1946563/000155485526000467/0001554855-26-000467-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | SXTP on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2023 |
| SEC CIK | 0001946563 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $1.0M |
| Net income | -$7.4M |
| Operating income | -$7.8M |
| Net margin | -732.5% |
| Operating margin | -771.6% |
| Revenue growth | +65.5% |
| Cash | $1.5M |
| Total assets | $5.4M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 1.7× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "These conditions, among others, raise substantial doubt about the ability of the Company to continue as a going concern for one year from the date these consolidated condensed financial statements are issued. 6 Management plans to fund operations of the Company through third party and related party debt/advances, private placement of restricted securities and the issuance of stock in a subsequent offering until such " | 10-Q 2026-08-14 |
| Cash and burn | $1.0M cash; operating cash flow -$2.2M a quarter. | Report 2026-06-30 |
| Shares outstanding | 3,516,988 (2026-08-14); 4,104,469 a year earlier; 5,799,535 three years earlier. 1y figure adjusted for splits (1-for-4 overall); 3y figure adjusted for splits (1-for-240 overall). | Cover page 2026-08-14 |
| Reverse splits, 3 years | 3; latest 1-for-4 on 2026-01-20 | Source 2026-01-20 |
| Shelf and offerings, 12 months | 1 S-3/F-3 shelf filings; 3 424B5 takedowns, 3 at the market | Latest 2026-03-13 |
| Exchange deficiency notices, 12 months | 1 (8-K item 3.01) | 8-K 2026-01-23 |
| Auditor | RBSM LLP, LAS VEGAS, Nevada, United States | PCAOB Form AP 2026-03-31 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $30K, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q2 2026 2026-06-30 | $208K | -$2.3M | -$2.2M | $1.0M | $150K | $1.1M | 10-Q 2026-08-14 |
| Q1 2026 2026-03-31 | $162K | -$2.1M | -$2.7M | $3.3M | $150K | $1.0M | 10-Q 2026-05-15 |
| Q4 2025 2025-12-31 | $303K | -$1.4M | -$1.7M | $1.5M | $150K | $1.0M | 10-K 2026-03-30 |
| Q3 2025 2025-09-30 | $438K | -$2.3M | -$2.1M | $4.1M | $150K | $944K | 10-Q 2025-11-13 |
| Q2 2025 2025-06-30 | $101K | -$1.7M | -$1.5M | $2.0M | $150K | $641K | 10-Q 2026-08-14 |
| Q1 2025 2025-03-31 | $164K | -$1.9M | -$1.6M | $3.5M | $150K | $665K | 10-Q 2026-05-15 |
| Q4 2024 2024-12-31 | $242K | -$2.0M | -$1.6M | $1.7M | $150K | $608K | 10-K 2026-03-30 |
| Q3 2024 2024-09-30 | $135K | -$2.2M | -$1.7M | $3.3M | $150K | $492K | 10-Q 2025-11-13 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document REGISTRATION STATEMENT | S-3 | 2026-08-14 |
| Latest annual report | 10-K | 2026-03-30 |
| Latest quarterly / interim | 10-Q | 2026-11-16 |
| Latest current report CURRENT REPORT | 8-K | 2026-11-06 |
| Latest proxy DEFINITIVE PROXY STATEMENT | DEF 14A | 2026-07-02 |
Source: SEC EDGAR submissions feed, 227 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -12.9% |
| 1 month | -42.4% |
| 3 months | -56.1% |
| Year to date | -74.5% |
| 1 year | -88.9% |
| From 52-week high | -90.0% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Other listings for this company
| Ticker | Name | Price |
|---|---|---|
| SXTPW | 60 Degrees Pharmaceuticals Inc. Warrant | $0.0260 |
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| ENLV | Enlivex Ltd. | $1.12 | -5.88% | $1.7M |
| HCWB | HCW Biologics Inc. | $0.8000 | +3.48% | $1.8M |
| XRTX | XORTX Therapeutics Inc. Common Shares | $1.04 | -5.45% | $1.9M |
| ARTL | Artelo Biosciences Inc. | $1.70 | -17.87% | $1.6M |
| ONCO | Onconetix Inc. | $2.91 | -9.35% | $1.9M |
| PPCB | Propanc Biopharma Inc. | $1.89 | -2.62% | $2.0M |
| APVO | Aptevo Therapeutics Inc. | $0.5486 | -7.66% | $1.5M |
| CMND | Clearmind Medicine Inc. Common Shares | $4.18 | -7.67% | $2.1M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier